The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Viking Therapeutics reported positive Phase 2 data for its oral weight loss drug, VK2735. According to reports, the oral formulation demonstrated a mean weight reduction of up to 12.2% from baseline over a 13-week period. The company noted that the weight loss was dose-dependent and did not reach a plateau during the trial timeframe.
Sign in to access this content
Sign InThese clinical results position Viking as a potential challenger to industry leaders like Eli Lilly and Novo Nordisk. Per market data, investors are increasingly focused on oral alternatives to traditional injectable GLP-1 therapies due to higher patient compliance. The dual GLP-1 and GIP receptor agonist approach continues to be a high-growth area within the biotech sector as firms race to capture market share.
VKTX shares are being monitored closely following these results, with price action reflecting sentiment as of the May 12, 2026 close. Looking ahead, broader market volatility driven by recent economic data, such as the US ADP Employment Change which came in at 109k, may influence capital flows into high-beta biotech stocks as investors weigh clinical progress against macroeconomic catalysts.